Eudaimonia Partners’s Gabelli Healthcare & Wellness Trust GRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-48,713
Closed -$418K 290
2023
Q3
$418K Sell
48,713
-597
-1% -$5.7K 0.1% 195
2023
Q2
$491K Buy
49,310
+567
+1% +$5.67K 0.11% 186
2023
Q1
$492K Buy
48,743
+221
+0.5% +$2.25K 0.12% 177
2022
Q4
$499K Buy
48,522
+2,279
+5% +$22.9K 0.12% 179
2022
Q3
$439K Buy
46,243
+4,303
+10% +$48K 0.11% 178
2022
Q2
$450K Buy
41,940
+1,377
+3% +$16K 0.08% 236
2022
Q1
$520K Buy
+40,563
New +$517K 0.09% 233
2021
Q3
$420K Buy
31,826
+272
+0.9% +$3.69K 0.08% 254
2021
Q2
$426K Buy
31,554
+271
+0.9% +$3.56K 0.08% 247
2021
Q1
$390K Sell
31,283
-366
-1% -$4.49K 0.08% 235
2020
Q4
$378K Buy
31,649
+324
+1% +$3.59K 0.08% 224
2020
Q3
$323K Buy
31,325
+381
+1% +$3.98K 0.08% 223
2020
Q2
$311K Buy
30,944
+356
+1% +$3.53K 0.12% 179
2020
Q1
$265K Sell
30,588
-2,788
-8% -$29.5K 0.12% 179
2019
Q4
$384K Buy
+33,376
New +$360K 0.15% 149

Other funds holding GRX

Eudaimonia Partners's GRX Position: Q4 2023 in Review

Eudaimonia Partners sold out of Gabelli Healthcare & Wellness Trust (GRX) in Q4 2023, closing a stake of 48,713 shares — an estimated $418K sold.

Eudaimonia Partners first reported a position in GRX in Q4 2019 and held it in 15 quarters. The position peaked at $520K in Q1 2022. 71 funds tracked by Wall St. Rank hold GRX as of Q4 2023.

  • Eudaimonia Partners reported no remaining Gabelli Healthcare & Wellness Trust position as of Q4 2023 after selling out during the quarter.
  • Eudaimonia Partners sold 48,713 Gabelli Healthcare & Wellness Trust shares in Q4 2023, an estimated $418K.
  • Eudaimonia Partners first reported a position in Gabelli Healthcare & Wellness Trust in Q4 2019 and held it in 15 quarters.
  • Eudaimonia Partners's Gabelli Healthcare & Wellness Trust position peaked at $520K in Q1 2022.
  • 71 funds tracked by Wall St. Rank held Gabelli Healthcare & Wellness Trust as of Q4 2023.

Based on Eudaimonia Partners's 13F filing for Q4 2023, filed 8 Feb 2024.